The Application of mRNA Vaccines in Cancer Therapies

mRNA immunotherapy works by presenting tumor-associated antigens to the patient's immune system, thereby training it to recognize and target cancer cells th at express these antigens. mRNA cancer vaccines have shown remarkable tolerability and safety in both clini cal and preclinical trials. mRNA cancer vaccines produce fewer adverse reactions compared to traditional ca ncer treatments such as chemotherapy and radiotherapy. These vaccines elicit a memory immune response, thereby significantly reducing the risk of cancer recurrence. Notably, in contrast to peptide-based cancer vaccines, mRNA vaccines circumvent the necessity for human leukocyte antigen (HLA) haplot ype matching, offering a broader applicability across diverse patient populations. mRNA vaccines can initiat e antigen expression more rapidly, and they do not carry the genetic risks associated with insertional mutage nesis, which is a concern with DNA vaccine. The therapeutic efficacy of mRNA-based cancer vaccines is fundamentally dependent on their ability to precisely target tumor-associated antigens, consequently eliciting robust cellular immune responses. Tumor antigens can be system atically classified into two distinct categories: tumor-specific antigens (TSAs), which are exclusively expressed on malignant cells and absent in normal tissues, and tumor-associated antigens (TAAs), which exhibit differential expression patterns between neoplastic and normal ce llular populations. Many different types of vaccines were developed to address multiple cancer types, includi ng melanoma, breast cancer, and pancreatic cancer.